All News
What is D2T PsA?
A proposal of definition in ABST0777
Thoughts:
A lot of features are extrapolated from the EULAR RA definition
RA & PsA population are hardly comparable
Lack of emphasis more problematic domains ie. dactylitis
Further work is required
@RheumNow #ACR23 https://t.co/A28e6XBME3
Aurelie Najm ( View Tweet)
Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation.
Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies
SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY
David Liew drdavidliew ( View Tweet)
Klein et al. 205 RA-ILD. MUC5B not significantly associated survival, although wide CIs, aHR 0.75 (0.45, 1.24). Abstr#0772 #ACR23 @RheumNow https://t.co/ZfIIr2BbbR https://t.co/47DPYWNpL9
Richard Conway ( View Tweet)
FAPα possible therapeutic biomarker target of pathogenic fibroblasts. #ACR23 Abs 0802 demonstrates potential therapeutic efficacy of fibroblast-targeted immunotherapy as a novel treatment in inflammatory disease. https://t.co/ZGUfC6PZxa @rheumnow https://t.co/jj9BeuvTuc
Dr. Rachel Tate ( View Tweet)
Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH
Richard Conway ( View Tweet)
Always great to see UCSD represent at #ACR23!
Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events
30% of events occurred postpartum
@RheumNow Abs#0722 https://t.co/CqZedfOlBC
Robert B Chao, MD ( View Tweet)
Are anti CCP3 the new anti CCP2 antibodies?
Not yet!
Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms
But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2
@RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw
Aurelie Najm ( View Tweet)
Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5
Dr. Antoni Chan ( View Tweet)
Non invasive screening for pulmonary involvement in early RA
Combination of PFT and Lung 🫁 US:
-50% with interstitial or focal changes or pleural effusion on US
-58% with abnormal DLCO
Correlation w/ higher disease activity.
Pathological meaning?
@RheumNow ABST 0393 #ACR23 https://t.co/BBcOEgcJK2
Aurelie Najm ( View Tweet)
WEAR study: adherence to wearable activity trackers in RA
Something that is consistent across all wearable studies is low adherence
Here under 50% for PRO + tracking
In an already selected population!
To implement, we need to make this better?
ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt
Aurelie Najm ( View Tweet)
Year in Review: Dr. P Seo
⭐️Does Pizza consumption favor improved dz activity in RA?
If in Italy
➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz
➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6)
➡️Mozzarella & olive oil showed beneficial effects
#ACR23 @RheumNow https://t.co/qZTzThI39e
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Towards more personalised care in rheumatoid arthritis #ACR23 @RheumNow https://t.co/roxtcX8QHI
Dr. Antoni Chan ( View Tweet)
RA as a young woman used to mean kids were only a distant thought.
Japanese RA pts n=280 asked whether RA onset meant wanting fewer children & why.
Confidence improving across the board over time.
We want to give our RA pts choices to live their life!
#ACR23 ABST0473 @RheumNow https://t.co/OHZM2J5qxS
David Liew drdavidliew ( View Tweet)
Year in Review: Dr. P Seo
Novel RA therapy on the horizon:
⭐️ABBV-3373
➡️ Adalimumab (ADA) + GC receptor modulator vs ADA
➡️ Phase II, 48 pts, previously failed MTX
➡️ Wk 12: better DAS28-CRP, ACR20/70
🚩71% of responders stayed in remission after switch to PBO
#ACR23 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Difficult to treat RA is not an homogeneous group!
Trajectory analysis 60months shows 4 different clusters
Cluster 2 = 1/3 of patients, do better but never reach LDA.
The ones Fibromyalgia, OA and other conditions blurring assessment?
#Abstract0382 #ACR23 @RheumNow https://t.co/dxxS7vCcMt
Aurelie Najm ( View Tweet)
Year in Review: Dr. P Seo
Novel RA therapy on the horizon:
⭐️Peresolimab
➡️ stimulates PD1
➡️ Phase II, 98 pts
➡️ tx-resistant to other therapies including biologics
➡️ Wk 12: better DAS28, ACR20, not ACR 50/70
#ACR23 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
YR in Review: Dr. Seo
🚩GLORIA Trial
RA pts > 65yo: prednisolone 5 mg/d x 2 yrs vs PBO + std care
➡️decr dz activity (DAS ⬇️0.37) but 24% incr ADE
🚩Extension:
➡️Tapered off pred over 3m and..
⭐️NO ADRENAL INSUFF
But, small incr in dz activity (DAS ⬆️0.23)
#ACR23 @RheumNow https://t.co/YQbS6C8ZT5
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA.
Why is it hard? I guess:
- theory ≠ practice
- too many other factors
- it's too easy not to
Yet I hope/believe, one day we'll do better.
#ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN
David Liew drdavidliew ( View Tweet)
If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year?
US Medicare data 2008-17
n=33,373
only 30% have a DMARD on file
(of which bDMARD <10%)
>5% on PNL alone
Do we hate old people with RA?😔
@JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0
David Liew drdavidliew ( View Tweet)
I underestimated how much joy not-bankrupting our healthcare system would bring me
ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party
@RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd
Mike Putman EBRheum ( View Tweet)
